Adicet Bio, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$122.1M | -$127.6M | -$152.0M | -$72.6M | -$61.4M |
| Operating expenses | $122.1M | $127.6M | $152.0M | $97.5M | $71.2M |
| Cash from operations | -$95.2M | -$92.4M | -$93.7M | -$44.8M | -$51.1M |
| Capital expenditure | $1.7M | $1.1M | $4.5M | $16.8M | $13.0M |
| Free cash flow | -$97.0M | -$93.5M | -$98.2M | -$61.5M | -$64.1M |
| Impairments | $0 | $0 | $19.5M | $0 | $0 |
| Total assets | $192.4M | $220.2M | $207.3M | $330.7M | $338.9M |
| Total liabilities | $33.1M | $33.6M | $37.1M | $38.4M | $35.8M |
Shares outstanding 9.3M
Annual filing data through FY ended December 31, 2025; float as of July 2, 2026.